Cost projections for oral non-peptide GLP-1 agonists — anyone have experience?

Dr.LipidDallas said:

It is worth asking what the claim would look like if it were false.

Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

sarah_TO said:

The manufacturing argument is the underrated one.

Bookmarking. The distinction being drawn above is the one nobody else makes.

Dr.LipidDallas said:

It is worth asking what the claim would look like if it were false.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

Adding the numbers, since they settle part of this. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

Moderator note: a couple of off-topic posts removed.